Ratings hVIVO plc

Equities

VENN

GB00B9275X97

Market Closed - London S.E. Other stock markets 16:35:13 02/05/2024 BST			5-day change	1st Jan Change
27.95 ^GBX	+0.54%		-1.06%	+17.68%

04-09	Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024
04-09	HVIVO swings to profit and commences annual dividends as outlook rosy	AN

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The firm trades with high earnings multiples: 21.57 times its 2023 earnings per share.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
HVIVO PLC	+17.68%	236M	-
MODERNA, INC.	+26.28%	42.68B	B-
IQVIA HOLDINGS INC.	-3.99%	42.4B	B
LONZA GROUP AG	+45.32%	40.04B	A
CELLTRION, INC.	-6.20%	28.31B	C
ICON PUBLIC LIMITED COMPANY	+6.36%	24.94B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	18.96B	B
MEDPACE HOLDINGS, INC.	+27.58%	12.3B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.95B	C+
BIO-TECHNE CORPORATION	-2.02%	11.55B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes